Navigation Links
Genelux Corporation Expands Board of Directors, Appointing Dennis Fenton, Former Amgen Executive
Date:1/24/2011

SAN DIEGO, Jan. 24, 2011 /PRNewswire/ -- Genelux Corporation, a privately held, clinical stage biopharmaceutical company developing diagnostic and therapeutic solutions for cancer and inflammatory diseases, today announced the appointment of Dr. Dennis Fenton, long-time Amgen executive, to the company's Board of Directors. Dr. Fenton's appointment expands the Genelux Corporation board to 5 members.  

"As someone who helped to build one of the world's most successful pharmaceutical companies from the ground up, Dr. Fenton has a wealth of experience and attributes that will enable him to make a tremendous contribution to the Genelux Board," said Aladar A. Szalay, Founder, Chairman and Chief Executive Officer. "He brings to this Directorship incredible professional breadth and depth.  A research scientist by training, Dr. Fenton worked in and led nearly every part of Amgen as it developed, building the most admired biotechnology manufacturing operation in the world.  I am honored to welcome Dr. Fenton to the Genelux Board as our second outside Director".

Dr. Fenton, age 59, retired in December 2007 after 26 years with Amgen, where he last served as Executive Vice President of Operations.  He was one Amgen's first employees, joining the company in 1982 during its first 12 months. Starting as a Research Scientist, he held positions of increasing responsibility, including Vice President of Research, Senior Vice President of Sales and Marketing, Senior Vice President of Operations and was Amgen's first Executive Vice President.

Prior to his tenure at Amgen, Dr. Fenton worked for Pfizer Central research in New Product Development from 1977 until 1981. Since his retirement from Amgen in 2008, he has been an independent consultant and a member of several boards including Amira, Kythera, CytomX, Xenoport, Genzyme, Rutgers University, the Keck Graduate Institute and the Biotechnology Institute. Dr. Fenton holds a PhD in Microbiology from Rutgers University.

About Genelux Corporation

Genelux Corporation was founded in 2001 with a mission to develop safe and effective diagnostic and therapeutic solutions for cancer and inflammatory diseases for which there are no effective treatments today. Genelux Corporation is headquartered in San Diego, California,

Genelux Forward Looking Statement

Statements made about Genelux Corporation, other than statements of historical fact, reflect Management's current beliefs and assumptions founded on the data and information currently available to us. Statements of the company's progress, results, timing of pre-clinical and clinical trials and projections for product pipelines are examples of forward-looking statements. By definition, such undertakings involve risks, uncertainties and assumptions, and are subject to a number of such factors that could cause actual results to differ substantially from statements made, including but not limited to: risks associated with the success of clinical trials, research and development programs, regulatory approval processes for clinical trials, competitive technologies and products, patents, inception and/or continuation of corporate and other strategic partnerships and the need for additional funding or financing.  


'/>"/>
SOURCE Genelux Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
10. Immunosyn Corporation Releases SF-1019 Study Results
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/8/2017)... -- Diplomat Pharmacy, Inc. (NYSE: DPLO)., has completed its acquisition ... care service center company based in Chantilly, ... management programs for leading pharmaceutical manufacturers and health care ... will join Envoy Health Management, LLC , as ... firms, and other service companies. Together, WRB and EnvoyHealth ...
(Date:5/4/2017)... May 4, 2017  A recent study published ... Ultraviolet-C light as a means of disinfection ... to reduce bioburden on anesthesia workstations. In the ... high-touch, complex medical equipment surfaces contaminated with three ... "This study further validates the body of ...
(Date:5/4/2017)... --  BioLife Solutions , Inc. (NASDAQ: BLFS ... clinical grade hypothermic storage and cryopreservation ... that the Company,s first quarter 2017 financial results will ... 2017, and that the Company will host a conference ... afternoon. Management will provide an overview of the Company,s ...
Breaking Medicine Technology:
(Date:5/24/2017)... (PRWEB) , ... May 24, 2017 , ... Myers Jackson ... his has the ability to sell luxury homes anywhere on the planet. The luxury ... county side from Hattiesburg to Houston city-scapes. A quick search of “11 Spyglass Hill ...
(Date:5/24/2017)... Soquel, California (PRWEB) , ... May 24, 2017 , ... If you are thinking of ... you are interested in business architecture, October is the perfect time to visit. , Business ... as an à la carte offering for individuals, as a 4-½ day package for individuals, ...
(Date:5/24/2017)... ... 2017 , ... Technique, technique, technique – with a dash of common sense. ... training and exercise or simply lifting heavy objects, advises Dr. Kaliq Chang, interventional pain ... Chang says. “Improper technique in lifting anything heavy or an attempt to lift too ...
(Date:5/23/2017)... YORK, NY (PRWEB) , ... May 23, 2017 ... ... makers in the pharmaceutical and medical device sectors, today announced the winners of ... Transformers • Entrepreneurs) represent the most influential people in the healthcare industry today. ...
(Date:5/23/2017)... ... May 23, 2017 , ... London, May 23, 2017: Walter Schindler, ... this month as a Guest Speaker and Contributor to a weeklong series of classes, ... Purpose. , Walter Schindler and SAIL Capital have received ...
Breaking Medicine News(10 mins):